Sirius-biotech has acquired from the National Cancer Institute of Genoa the patent for the mAb C6. The mAb C6 recognizes a novel fibronectin epitope unmasked by the insertion of the extra-domain B. This antibody, specifically reacting with neoforming blood vessels, represents a new tool for the targeting of tissues undergoing neoangiogenesis and for the study of novel fibronectin […]
Bone reconstruction evidence after tissue engineering study